Display options
Cite
Papakostas GI, Hallett LA, Smith J, et al. A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat. 2007;3(1):169-72doi: 10.2147/nedt.2007.3.1.169.
Papakostas, G. I., Hallett, L. A., Smith, J., Tossani, E., Mascarini, A., Burns, A. M., Birnbaum, R. J., Fava, M., & Alpert, J. E. (2007). A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatric disease and treatment, 3(1), 169-72. https://doi.org/10.2147/nedt.2007.3.1.169
Papakostas, George I, et al. "A survey of five antidepressant properties influencing clinician's treatment choices in MDD." Neuropsychiatric disease and treatment vol. 3,1 (2007): 169-72. doi: https://doi.org/10.2147/nedt.2007.3.1.169
Papakostas GI, Hallett LA, Smith J, Tossani E, Mascarini A, Burns AM, Birnbaum RJ, Fava M, Alpert JE. A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat. 2007 Feb;3(1):169-72. doi: 10.2147/nedt.2007.3.1.169. PMID: 19300547; PMCID: PMC2654520.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2007 Feb;3(1):169-72. doi: 10.2147/nedt.2007.3.1.169.

A survey of five antidepressant properties influencing clinician's treatment choices in MDD.

Neuropsychiatric disease and treatment

George I Papakostas, Lindsay A Hallett, Juliana Smith, Eliana Tossani, Alessandra Mascarini, Alana M Burns, Robert J Birnbaum, Maurizio Fava, Jonathan E Alpert

Affiliations

  1. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. [email protected]

PMID: 19300547 PMCID: PMC2654520 DOI: 10.2147/nedt.2007.3.1.169

Abstract

INTRODUCTION: The goal of the present work was to examine how clinicians' perceptions of the properties of antidepressants may influence their choice of antidepressants when treating major depressive disorder (MDD).

METHODS: 273 of 682 (40%) clinicians attending a psychopharmacology review course responded to a questionnaire designed to explore their practices and perceptions with regards to antidepressant pharmacotherapy.

RESULTS: Most clinicians ranked efficacy (57.3%) as the most important factor when selecting antidepressants, followed by safety (23.0%), tolerability (9.4%), rapidity of action (5.2%), and cost (4.9%). However, when presented with hypothetical scenarios in which there was a difference in efficacy between two antidepressant agents, the relative safety, tolerability, and cost of the two agents significantly influenced the likelihood of choosing one antidepressant over another. In fact, clinicians required progressively greater differences in efficacy between two agents in order to select one antidepressant over another given a difference in terms of their safety than tolerability, or their tolerability than cost (p < 0.0001 all comparisons).

CONCLUSIONS: When selecting an antidepressant, clinicians appear to be most influenced by efficacy, followed by safety. Rapidity of action and cost may be less salient considerations in clinical practice. Further research is necessary to elucidate factors that influence clinicians' choice of antidepressants.

Keywords: antidepressant; depression; preferences; prescribing; survey

References

  1. J Clin Psychiatry. 2006 Jun;67(6):850-64 - PubMed
  2. Eur Neuropsychopharmacol. 2009 Jan;19(1):34-40 - PubMed
  3. Evid Rep Technol Assess (Summ). 1999 Mar;(7):1-4 - PubMed
  4. Ann Pharmacother. 2000 Jan;34(1):10-4 - PubMed
  5. Arch Gen Psychiatry. 1998 Apr;55(4):310-6 - PubMed
  6. JAMA. 2002 Apr 10;287(14):1840-7 - PubMed
  7. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):177-87 - PubMed
  8. Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45 - PubMed
  9. Aust N Z J Psychiatry. 1999 Oct;33(5):642-9 - PubMed

Publication Types

Grant support